$17.56
3.23% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US89422G1076
Symbol
TVTX
Sector
Industry

Travere Therapeutics Inc Stock price

$17.56
+2.45 16.21% 1M
-0.30 1.68% 6M
+0.14 0.80% YTD
+11.39 184.60% 1Y
-6.62 27.38% 3Y
+1.13 6.88% 5Y
-9.19 34.36% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.55 3.23%
ISIN
US89422G1076
Symbol
TVTX
Sector
Industry

Key metrics

Market capitalization $1.56b
Enterprise Value $1.64b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.99
P/S ratio (TTM) P/S ratio 5.70
P/B ratio (TTM) P/B ratio 47.50
Revenue growth (TTM) Revenue growth 49.29%
Revenue (TTM) Revenue $273.53m
EBIT (operating result TTM) EBIT $-225.09m
Free Cash Flow (TTM) Free Cash Flow $-160.66m
Cash position $322.24m
EPS (TTM) EPS $-2.80
P/E forward negative
P/S forward 3.95
EV/Sales forward 4.15
Short interest 12.06%
Show more

Is Travere Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Travere Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Travere Therapeutics Inc forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Travere Therapeutics Inc forecast:

Buy
87%
Hold
13%

Financial data from Travere Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
274 274
49% 49%
100%
- Direct Costs 57 57
2% 2%
21%
216 216
70% 70%
79%
- Selling and Administrative Expenses 180 180
1% 1%
66%
- Research and Development Expense 215 215
8% 8%
79%
-179 -179
38% 38%
-65%
- Depreciation and Amortization 46 46
1% 1%
17%
EBIT (Operating Income) EBIT -225 -225
33% 33%
-82%
Net Profit -227 -227
41% 41%
-83%

In millions USD.

Don't miss a Thing! We will send you all news about Travere Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Travere Therapeutics Inc Stock News

Negative
Seeking Alpha
about 9 hours ago
Travere Therapeutics focuses on rare kidney and metabolic diseases, with strong revenue growth from recently approved Filspari and a narrowing loss in Q1 2024. Analysts generally remain bullish, with multiple Buy ratings and price targets ranging from $22 to $45 a share on the stock that current trades around $17.00 a share. The company did suffer a bit of setback last week as the FDA moved bac...
Neutral
Business Wire
5 days ago
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for traditional approval of FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of Januar...
Neutral
Business Wire
8 days ago
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 35,900 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 201...
More Travere Therapeutics Inc News

Company Profile

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Head office United States
CEO Eric Dube
Employees 385
Founded 2008
Website www.travere.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today